PREPARATION OF [I-131] LIPIODOL AS A HEPATOMA THERAPEUTIC AGENT

An isotopic exchange method was used to label lipiodol with I-131. The labelling efficiency was > 92.5%, and the radiochemical purity of [I-131]lipiodol was above 98% as determined by ITLC. The influencing factors e.g. the beating temperature, reaction time, pH and storage conditions were studied and the optimum conditions were determined. In a pilot study injecting [I-131]lipiodol for the treatment of hepatoma, about 70% of hepatoma patients had a response to the treatment with a reduction of alpha-fetoprotein and decrease of hepatoma sizes. The overall median survival was 9 months (range 2-17 months).